Intra and intersession reliability of the Run RocketTM in recreationally trained participants

Sprint performance plays an important role in the success of many sports including track and field and team-based sports. Resisted sprint equipment has shown to be an effective method to increase sprint velocity and acceleration. The aim of the study was to determine the intrasession and intersession (7 days) reliability of a commercially available resisted sprint machine in recreationally trained individuals for two resistance settings. Fourteen recreationally active participants partook in the study (male = 10, female = 4) over a 7-day period. Three maximal 15m sprints, at two resistance levels (R0 and R5), were undertaken in a randomised order (6 sprints in total at each trial). Intrasession (comparison of the first 3 sprints for each trial) and intersession (mean of the 3 sprints for both trials) correlation coefficient (ICC), coefficients of variation (%CV), average variability, SEM and minimal detectable difference were calculated for 5 and 15m for both resistance levels. Intrasession reliability was very large to nearly perfect across both distances and resistance levels (ICC range 0.79-0.98), %CV ranged between 2.4-5.8% with larger values seen during the first trial for three of the four indices. Intersession reliability was very large to nearly perfect across all variables (ICC range 0.87-0.97), %CV was small and ranged between 2.0-4.1%. Average variability was small for all measurements. The Run RocketTM showed high intra and intersession reliability. The results show that this equipment could be reliably used within a sprint programme for recreationally trained individuals

The effects of variable resistance using chains on bench throw performance in trained rugby players

This study sought to determine the effects of variable resistance using chain resistance on bench throw performance. Eight male rugby union players (19.4 ± 2.3 y, 88.8 ± 6.0 kg, 1RM 105.6 ± 17.0 kg) were recruited from a national league team. In a randomised cross-over design participant’s performed three bench throws at 45% one repetition maximum (1RM) at a constant load (No Chains) or a variable load (30% 1RM constant load, 15% 1RM variable load; Chains) with seven days between conditions. For each repetition the peak and mean velocity, peak power, peak acceleration and time to peak velocity were recorded. Differences in peak and mean power were very likely trivial and unclear between the Chains and No Chains conditions, respectively. Possibly greater peak and likely greater mean bar velocity were accompanied by likely to most likely greater bar velocity between 50-400 ms from initiation of bench press in the Chains compared to the No Chains condition. Accordingly, bar acceleration was very likely greater in the Chains compared to the No Chains condition. In conclusion, these results show that the inclusion of chain resistance can acutely enhance several variables in the bench press throw and gives support to this type of training

The Magnitude of Rapid Weight Loss and Rapid Weight Gain in Combat Sport Athletes Preparing for Competition: A Systematic Review

Combat sport athletes typically engage in a process called making weight, characterized by rapid weight loss (RWL) and subsequent rapid weight gain (RWG) in the days preceding competition. These practices differ across each sport, but no systematic comparison of the size of the changes in body mass exists. The aim was to determine the magnitude of RWL and RWG in combat sport athletes preparing for competition. The review protocol was preregistered with PROSPERO (CRD42017055279). In eligible studies, athletes prepared habitually with a RWL period ≤7 days preceding competition. An electronic search of EBSCOhost (CINAHL Plus, MEDLINE, and SPORTDiscus) and PubMed Central was performed up to July 2018. Sixteen full-text studies (total 4,432 participants; 156 females and 4,276 males) were included, providing data from five combat sports (boxing, judo, mixed martial arts, taekwondo, and wrestling). Three studies reported RWL and 14 studies reported RWG. Duration permitted for RWG ranged 3–32 hr. The largest changes in body mass occurred in two separate mixed martial arts cohorts (RWL: 7.4 ± 1.1 kg [∼10%] and RWG: 7.4 ± 2.8 kg [11.7% ± 4.7%]). The magnitude of RWG appears to be influenced by the type of sport, competition structure, and recovery duration permitted. A cause for concern is the lack of objective data quantifying the magnitude of RWL. There is insufficient evidence to substantiate the use of RWG as a proxy for RWL, and little data are available in females. By engaging in RWG, athletes are able to exploit the rules to compete up to three weight categories higher than at the official weigh-in

Multiaperture UBVRIzJHKUBVRIzJHK Photometry of Galaxies in the Coma Cluster

We present a set of $UBVRIzJHK_s$ photometry for 745 $J+H$ band selected objects in a $22.5' \times 29.2'$ region centered on the core of the Coma cluster. This includes 516 galaxies and is at least 80% complete to H=16, with a spectroscopically complete sample of 111 cluster members (nearly all with morphological classification) for $H < 14.5$. For each object we present total \cite{kron80} magnitudes and aperture photometry. As an example, we use these data to derive color-magnitude relations for Coma early-type galaxies, measure the intrinsic scatter of these relations and its dependence on galaxy mass, and address the issue of color gradients. We find that the color gradients are mild and that the intrinsic scatter about the color-magnitude relation is small ($\sim 0.05$ mag in $U-V$ and less than $\sim 0.03$ in $B-R$, $V-I$ or $J-K$). There is no evidence that the intrinsic scatter varies with galaxy luminosity, suggesting that the cluster red sequence is established at early epochs over a range of $\sim 100$ in stellar mass.Comment: 41 pages, 5 figures, 18 data tables attached to source files or available on request from R. De propris. Accepted for publication in Astrophysical Journal Supplement Serie

Conservation and diversity in expression of candidate genes regulating socially-induced female-male sex change in wrasses

International audienc

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

OBJECTIVES: Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine kinase (SRC) in the oncogenesis of epithelial ovarian cancer (EOC) or primary peritoneal carcinoma (PPC). The Gynecologic Oncology Group (GOG) conducted a Phase II trial to evaluate the efficacy and safety of dasatinib, an oral SRC-family inhibitor in EOC/PPC, and explored biomarkers for possible association with clinical outcome. METHODS: Eligible women had measurable, recurrent or persistent EOC/PPC and had received one or two prior regimens which must have contained a platinum and a taxane. Patients were treated with 100mg orally daily of dasatinib continuously until progression of disease or adverse effects prevented further treatment. Primary endpoints were progression-free survival (PFS)≥6months and response rate. Serial plasma samples were assayed for multiple biomarkers. Circulating free DNA was quantified as were circulating tumor and endothelial cells. RESULTS: Thirty-five (35) patients were enrolled in a two-stage sequential design. Of the 34 eligible and evaluable patients, 20.6% (90% confidence interval: 10.1%, 35.2%) had a PFS≥6months; there were no objective responses. Grade 3-4 toxicities were gastrointestinal (mostly nausea and emesis; n=4), pulmonary (dyspnea and/or pleural effusion; n=4) and pain (n=5), and infrequent instances of anemia, malaise, insomnia, rash, and central nervous system hemorrhage. Lack of clinical activity limited any correlation of biomarkers with outcome. CONCLUSION: Dasatinib has minimal activity as a single-agent in patients with recurrent EOC/PPC

The First Hour of Extra-galactic Data of the Sloan Digital Sky Survey Spectroscopic Commissioning: The Coma Cluster

On 26 May 1999, one of the Sloan Digital Sky Survey (SDSS) fiber-fed spectrographs saw astronomical first light. This was followed by the first spectroscopic commissioning run during the dark period of June 1999. We present here the first hour of extra-galactic spectroscopy taken during these early commissioning stages: an observation of the Coma cluster of galaxies. Our data samples the Southern part of this cluster, out to a radius of 1.5degrees and thus fully covers the NGC 4839 group. We outline in this paper the main characteristics of the SDSS spectroscopic systems and provide redshifts and spectral classifications for 196 Coma galaxies, of which 45 redshifts are new. For the 151 galaxies in common with the literature, we find excellent agreement between our redshift determinations and the published values. As part of our analysis, we have investigated four different spectral classification algorithms: spectral line strengths, a principal component decomposition, a wavelet analysis and the fitting of spectral synthesis models to the data. We find that a significant fraction (25%) of our observed Coma galaxies show signs of recent star-formation activity and that the velocity dispersion of these active galaxies (emission-line and post-starburst galaxies) is 30% larger than the absorption-line galaxies. We also find no active galaxies within the central (projected) 200 h-1 Kpc of the cluster. The spatial distribution of our Coma active galaxies is consistent with that found at higher redshift for the CNOC1 cluster survey. Beyond the core region, the fraction of bright active galaxies appears to rise slowly out to the virial radius and are randomly distributed within the cluster with no apparent correlation with the potential merger of the NGC 4839 group. [ABRIDGED]Comment: Accepted in AJ, 65 pages, 20 figures, 5 table

BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers

Background: The K3326X variant in BRCA2 (BRCA2*c.9976A&gt;T; p.Lys3326*; rs11571833) has been found to be associated with small increased risks of breast cancer. However, it is not clear to what extent linkage disequilibrium with fully pathogenic mutations might account for this association. There is scant information about the effect of K3326X in other hormone-related cancers. Methods: Using weighted logistic regression, we analyzed data from the large iCOGS study including 76 637 cancer case patients and 83 796 control patients to estimate odds ratios (ORw) and 95% confidence intervals (CIs) for K3326X variant carriers in relation to breast, ovarian, and prostate cancer risks, with weights defined as probability of not having a pathogenic BRCA2 variant. Using Cox proportional hazards modeling, we also examined the associations of K3326X with breast and ovarian cancer risks among 7183 BRCA1 variant carriers. All statistical tests were two-sided. Results: The K3326X variant was associated with breast (ORw = 1.28, 95% CI = 1.17 to 1.40, P = 5.9x10- 6) and invasive ovarian cancer (ORw = 1.26, 95% CI = 1.10 to 1.43, P = 3.8x10-3). These associations were stronger for serous ovarian cancer and for estrogen receptor–negative breast cancer (ORw = 1.46, 95% CI = 1.2 to 1.70, P = 3.4x10-5 and ORw = 1.50, 95% CI = 1.28 to 1.76, P = 4.1x10-5, respectively). For BRCA1 mutation carriers, there was a statistically significant inverse association of the K3326X variant with risk of ovarian cancer (HR = 0.43, 95% CI = 0.22 to 0.84, P = .013) but no association with breast cancer. No association with prostate cancer was observed. Conclusions: Our study provides evidence that the K3326X variant is associated with risk of developing breast and ovarian cancers independent of other pathogenic variants in BRCA2. Further studies are needed to determine the biological mechanism of action responsible for these associations

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Long noncoding RNAs (lncRNAs) are commonly dys-regulated in tumors, but only a handful are known toplay pathophysiological roles in cancer. We inferredlncRNAs that dysregulate cancer pathways, onco-genes, and tumor suppressors (cancer genes) bymodeling their effects on the activity of transcriptionfactors, RNA-binding proteins, and microRNAs in5,185 TCGA tumors and 1,019 ENCODE assays.Our predictions included hundreds of candidateonco- and tumor-suppressor lncRNAs (cancerlncRNAs) whose somatic alterations account for thedysregulation of dozens of cancer genes and path-ways in each of 14 tumor contexts. To demonstrateproof of concept, we showed that perturbations tar-geting OIP5-AS1 (an inferred tumor suppressor) andTUG1 and WT1-AS (inferred onco-lncRNAs) dysre-gulated cancer genes and altered proliferation ofbreast and gynecologic cancer cells. Our analysis in-dicates that, although most lncRNAs are dysregu-lated in a tumor-specific manner, some, includingOIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, synergis-tically dysregulate cancer pathways in multiple tumorcontexts

Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates. Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]-positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS. Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR = 1.27, 95% confidence interval [CI] = 1.23 to 1.31, P = 8.2 x 10(53)). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR = 1.22, 95% CI = 1.17 to 1.28, P = 7.2 x 10(-20)). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19% risk for those at the 90th percentile of PRS. Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management